Area of research
Public Health, Environmental and Occupational Health · Hematology
Research interest
Research interests include Acute Lymphoblastic Leukemia research, Acute Myeloid Leukemia Research, Lymphoma Diagnosis and Treatment, and Childhood Cancer Survivors' Quality of Life.
Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children’s Oncology Group study
MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231
Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children’s Oncology Group study
Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children’s Oncology Group report
The genomic landscape of pediatric acute lymphoblastic leukemia
Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma
Sex‐based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children’s Oncology Group report
Association of Inherited Genetic Factors With Drug-Induced Hepatic Damage Among Children With Acute Lymphoblastic Leukemia
Germline RUNX1 variation and predisposition to childhood acute lymphoblastic leukemia
Children’s Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia
Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children’s Oncology Group AALL0434
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia
COG AALL0434: A randomized trial testing nelarabine in newly diagnosed t-cell malignancy.
PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia
Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children’s Oncology Group (COG)
Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia
Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children’s oncology group (COG) clinical trials
MLL rearrangements impact outcome in HOXA-deregulated T-lineage acute lymphoblastic leukemia: a Children’s Oncology Group Study
Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T‐cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434
T-Lymphoblastic Leukemia (T-ALL) Shows Excellent Outcome, Lack of Significance of the Early Thymic Precursor (ETP) Immunophenotype, and Validation of the Prognostic Value of End-Induction Minimal Residual Disease (MRD) in Children’s Oncology Group (COG) Study AALL0434
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
High-Throughput Sequencing Detects Minimal Residual Disease in Acute T Lymphoblastic Leukemia